Physician profile
Gurpreet Narula
NPI 1619908597
$21,430.61
in general payments reported to CMS, 2019-2025
74 companies · $2,385 in 2025
The $2,385 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,970 · 2020: $2,652 · 2021: $3,190 · 2022: $2,719 · 2023: $3,539 · 2024: $2,976 · 2025: $2,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,794 · Education: $80.46 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,793.82 |
| Education | $80.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,479.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,026.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,494.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $1,484.06 | 2019-2025 | Rexulti |
| Abbvie INC. | $959.09 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $851.96 | 2019-2024 | Spravato, Xarelto |
| Vanda Pharmaceuticals INC. | $786.03 | 2019-2024 | Fanapt, Hetlioz |
| Corcept Therapeutics | $635.47 | 2019-2025 | Korlym |
| Pfizer INC. | $630.86 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.26 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Allergan, INC. | $478.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $426.87 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $415.35 | 2019-2023 | Livalo, Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $401.57 | 2021-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $383.95 | 2021-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $371.21 | 2023-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $293.37 | 2019-2022 | |
| Cequr Corporation | $289.38 | 2024-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $274.90 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $271.11 | 2021-2025 | Ztlido |
| Mannkind Corporation | $258.74 | 2019-2025 | |
| Amgen INC. | $252.62 | 2019-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $250.86 | 2023-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $241.96 | 2022-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $210.98 | 2024-2025 | Voquezna |
| Horizon Therapeutics Plc | $187.76 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $178.67 | 2023-2025 | Gemtesa, Aptiom |
| Sanofi-Aventis U.S. LLC | $166.15 | 2019-2022 | |
| Grifols USA, LLC | $165.76 | 2019 | |
| Amarin Pharma, INC. | $153.43 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $151.22 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Edwards Lifesciences Corporation | $147.57 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $147.27 | 2022-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $143.94 | 2019 | |
| Acadia Pharmaceuticals INC | $125.31 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $120.05 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.88 | 2019-2025 | Trintellix |
| Abbott Laboratories | $114.27 | 2021-2025 | Freestyle Libre 3 |
| Sk Life Science, INC. | $113.58 | 2020-2021 | |
| Eisai INC. | $94.94 | 2020-2022 | |
| Lilly USA, LLC | $80.67 | 2021-2023 | Jardiance, Mounjaro |
| Verona Pharma, INC. | $78.33 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.14 | 2021-2023 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $77.41 | 2025 | |
| Inogen, INC. | $73.19 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Genzyme Corporation | $70.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.30 | 2020-2025 | Eliquis |
| Aimmune Therapeutics, INC. | $61.53 | 2025 | Zenpep |
| Alkermes, INC. | $56.27 | 2022-2024 | Lybalvi |
| Medtronic, INC. | $55.45 | 2025 | Minimed 780g |
| Biogen, INC. | $55.42 | 2021-2022 | |
| Medicure Pharma INC. | $54.08 | 2022-2024 | Zypitamag |
| Intra-Sana Laboratories | $52.10 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ironwood Pharmaceuticals, INC | $50.54 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $43.50 | 2021 | |
| Shire North American Group INC | $42.13 | 2019 | |
| Astellas Pharma US INC | $41.40 | 2019-2020 | |
| Valeritas, INC. | $39.97 | 2019 | |
| Shield Therapeutics INC | $34.46 | 2023 | Accrufer |
| Exact Sciences Corporation | $34.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $29.10 | 2019 | |
| Philips North America LLC | $26.64 | 2019-2020 | |
| Mylan Specialty L.P. | $25.95 | 2021-2024 | Yupelri |
| Boston Scientific Corporation | $22.50 | 2025 | Bodyguardian |
| Arcutis Biotherapeutics, INC. | $17.10 | 2023 | |
| Sequel Med Tech, LLC | $16.88 | 2025 | Twiist |
| Melinta Therapeutics, LLC | $16.63 | 2019 | |
| Esperion Therapeutics, INC. | $15.78 | 2024 | Nexletol |
| Insulet Corporation | $15.75 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.68 | 2024 | Lifevest |
| Nestle Healthcare Nutrition INC. | $15.32 | 2022 | |
| Zealand Pharma US, INC. | $13.65 | 2021 | |
| W. L. Gore & Associates, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.